Overview

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Eszopiclone